Sunshine Biopharma Inc. - התחייבויות לטווח ארוך של החברה SBFM

Sunshine Biopharma (SBFM) is competing for the oral tumor treatment market, seeking to establish partnerships to protect its intellectual property. Business prospects rely on the efficacy of KAb-201 against resistance and the success of tests on solid neoplasms. Canadian production combines the manufacture of generics with scientific research, and the indicator is 0.00. This price chart below clearly demonstrates the market dynamics of this biotechnology venture.

Sunshine Biopharma developments in oncology and generic drug trading are directly reflected in the company's long-term debt status. This metric aggregates all credit obligations with a maturity of more than one year, determining the overall leverage level. An increase in this indicator signals the attraction of borrowed capital to finance research or raw material procurement. It is critical for investors to correlate debt dynamics with the success of clinical trials. Excessive leverage increases the risk of default should the market value of shares decline.